Cost of surviving catastrophic illness

SYRACUSE, N.Y., Dec. 31 (UPI) -- The average cost of surviving a U.S. heart attack or stroke is $100,500, and much of it is not covered by standard health insurance, an insurance firm says.
Source: Health News - - Category: Consumer Health News Source Type: news

Related Links:

This study sought to investigate what could be learned from how these men have fared. The men were born in 1925-1928 and similar health-related data from questionnaires, physical examination, and blood samples are available for all surveys. Survival curves over various variable strata were applied to evaluate the impact of individual risk factors and combinations of risk factors on all-cause deaths. At the end of 2018, 118 (16.0%) of the men had reached 90 years of age. Smoking in 1974 was the strongest single risk factor associated with survival, with observed percentages of men reaching 90 years being 26.3, 25.7, ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 21 June 2019Source: Canadian Journal of CardiologyAuthor(s): Mark Canney, Mila Tang, Lee Er, Sean J. Barbour, Ognjenka Djurdjev, Adeera Levin, CanPREDDICT InvestigatorsAbstractBackgroundUsing standard cut-offs derived from healthy adults, high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are frequently elevated in patients with reduced glomerular filtration rate (GFR), with unclear implications. We sought to compare GFR-specific cut-offs of each biomarker to standard cut-offs for discrimination of cardiovascular risk in asymptomatic pa...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 21 June 2019Source: American Heart JournalAuthor(s): Bernardete Weber, Ângela C Bersch-Ferreira, Camila R Torreglosa, Aline Marcadenti, Enilda S Lara, Jacqueline T da Silva, Rosana P Costa, Renato H N Santos, Otavio Berwanger, Rosa Bosquetti, Raira Pagano, Luis G S Mota, Juliana D de Oliveira, Rafael M Soares, Andrea P Galante, Suzana A da Silva, Fernando G Zampieri, Cristiane Kovacs, Fernanda C Amparo, Priscila MoreiraAbstractBackgroundAppropriate dietary recommendations represent a key part of secondary prevention in cardiovascular disease (CVD).ObjectiveWe evaluated the effective...
Source: American Heart Journal - Category: Cardiology Source Type: research
Conclusions: Genotype-guided strategies could reduce the rates of cardiovascular events without increasing bleeding events compared with conventional treatment in ACS. Future multi-center genotype-based RCTs are required to confirm these findings. PMID: 31215825 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
Conclusion: Introducing extended-duration VTE prophylaxis with betrixaban in the UK would accrue substantial savings annually over the next 5 years compared to current prophylaxis. Clinical trial registration: identifier is NCT01583218. PMID: 31215264 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Patients whose surgeons had been reported for unprofessional behavior were at increased risk for complications such as wound infections, pneumonia, blood clots, kidney failure, stroke and heart attack.
Source: WebMD Health - Category: Consumer Health News Source Type: news
ConclusionsReversal of anticoagulation appears safe after LVAD-associated intracranial hemorrhage, though inadequate reversal was common. Resumption of warfarin ± antiplatelet was associated with fewer fatal and nonfatal thrombotic events compared with antiplatelets alone, though more nonfatal hemorrhage events occurred.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
This study presents the results of over 10-year (median 133 months, range 95–149) safety follow-up of VIF-CAD patients. Overall, 12 (36.4%) patients died in VIF and 8 (42.1%) in Placebo group (P = .68). Cardiovascular mortality was 12/33 (36.4%) in the VIF group and 6/19 (31.6%) in Placebo group (P = .73). Two Placebo patients died due to malignancies, but no VIF patients (P = .17). The Kaplan–Meier curves of combined endpoint: cardiovascular mortality, myocardial infarction and stroke were similar for both patient groups (P = .71). Odds ratio of Placebo group increa...
Source: American Heart Journal - Category: Cardiology Source Type: research
The effect of antipsychotic (AP) drugs on risk of stroke and myocardial infarction (MI) remains unclear due to methodological limitations of, and inconsistencies across, existing studies. We aimed to systemati...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Research article Source Type: research
The research found no decrease in major heart events in people taking vitamin D supplements. There was no drop in heart attack rates. No drop in stroke. No drop in death from any cause
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: Cardiology | Health | Health Insurance | Heart | Heart Attack | Insurance | Stroke